Journal of Virology · 2021 · 18 citations · 45 references
Life SciencesMolecular BiologyOncologyGene DeliveryMolecular VirologyVirologyAnimal VirusesOncogenic VirusesOncolytic Virus TherapyViral GeneticsViral InfectionsViral ReplicationCytopathic EffectsOncogenic RetrovirusesOncolytic Viral TherapyOncolytic Viral VectorsReplication-competent VectorsViral Dna ReplicationViral EngineeringViral Lifecycle Targeting
The infectivity of certain retroviruses is limited to dividing cells, which makes them attractive tools for targeting cancer cell proliferation. Previously developed replication-competent gammaretroviral vectors spread efficiently in rapidly dividing cancer cells, but not in cancer cells that divide more slowly. In contrast to rapidly proliferating transplantable mouse tumors, slow proliferation is a hallmark of human cancers and may have contributed to the clinical failure of the preclinically promising Murine Leukemia Virus vector Toca511 which failed to show efficacy in a phase 3 clinical trial in patients with glioblastoma. The studies presented in our manuscript show that oncolytic Foamy Virus (oFV) vectors are capable of persisting unintegrated in quiescent cells and resuming their life cycle once the cells start dividing again. This property of oFVs, together with their lack of pathogenicity and their ability to catalyze the fusion of infected cancer cells, makes them an attractive platform for further investigation.
45
Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy
Stephen J. Russell, Mark J. Federspiel, Kah-Whye Peng et al. · Mayo Clinic Proceedings · 2014 · 272 citations
Medicine, Immunology, Oncology +14